SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced on July 2, 2025, that its Compensation Committee has granted inducement awards to seventeen new employees under the company's 2024 Inducement Plan. These awards include non-qualified stock options to purchase 35,607 shares of common stock and 29,571 restricted stock units (RSUs). The stock options have an exercise price of $21.24 per share, reflecting Acadia's closing trading price on the grant date, and will vest over four years. The RSUs will also vest over four years, with specific vesting schedules tied to anniversaries of the grant date. These grants were approved in accordance with Nasdaq Listing Rule 5635(c)(4) as part of the company's effort to incentivize its new employees.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.